Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa

View ORCID ProfileDvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Jessica More, Linda-Gail Bekker, Pamina Gorbach, Thomas J. Coates, Landon Myer
doi: https://doi.org/10.1101/2021.05.04.21256514
Dvora Leah Joseph Davey
1Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
3The Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dvora Leah Joseph Davey
  • For correspondence: dvoradavey@ucla.edu
Rufaro Mvududu
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nyiko Mashele
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maia Lesosky
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nehaa Khadka
1Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica More
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda-Gail Bekker
3The Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamina Gorbach
1Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J. Coates
4David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Landon Myer
2Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Oral pre-exposure prophylaxis (PrEP) is a safe and effective prevention strategy to reduce women’s risk of HIV in pregnancy and postpartum. Effective PrEP requires daily PrEP adherence, but little is known about maternal PrEP continuation and risk factors that influence optimal PrEP use.

Methods The PrEP in pregnancy and postpartum (PrEP-PP) study is an ongoing cohort study that enrolled consenting pregnant, HIV-uninfected women at first antenatal care (ANC) visit, followed through 12-months postpartum. HIV-uninfected women and girls ≥16-years who were eligible for the study received HIV prevention counseling and were offered PrEP. Interviewers collected socio-demographic, behavioral data from participants at each visit. We analyzed the proportion of women who initiated PrEP and the proportion who continued on PrEP after 3-months with associated correlates, including side effects whilst on PrEP, by estimating the prevalence ratio (95% CI) adjusting for a priori confounders.

Results Between Aug’19 and Feb’21, we enrolled 891 pregnant women (median gestation=21wks; age=26yrs). Following PrEP counseling, 90% of women initiated PrEP at their first ANC visit (n=801); 60% were married or cohabiting. Three-quarters of women on PrEP returned for a repeat prescription at 1-month; 62% returned at 3-months. One-third of women on PrEP reported a side effect, mostly nausea/vomiting, dizziness, and headache. Women on PrEP in the 1st or 2nd trimester had higher odds of reporting side effects (aOR=2.61; 95%CI=1.17-5.84) vs. postpartum women. Women who reported side effects continued with PrEP less than those who did not report side effects (aPR=0.88; 95% CI=0.78-0.99) adjusting for covariates. Women who had ≥1 previous pregnancy (aPR=0.76;95%CI=0.59-1.00) or were postpartum (aPR=0.86;95%CI=0.75-0.99) continued less than women who were primigravid or pregnant. Women who reported having an HIV+ partner (aPR= 1.70;95% CI=1.55-1.86) or unknown partner serostatus (aPR=1.14;95%CI=1.01-1.29) were more likely to continue on PrEP than those who had HIV-negative partners.

Conclusion PrEP initiation and early continuation were high in ANC in this setting. Being postpartum and experiencing side effects were associated with lower PrEP continuation, presenting an opportunity for improved clinical management and counseling during pregnancy of nausea/vomiting to address early, transient side effects. Interventions for postpartum women on PrEP are urgently needed.

Clinical Trial Number NCT03826199

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT03826199

Funding Statement

This study was supported through grants from the National Institute of Mental Health (TC and LM; R01MH116771) and Fogarty International Center (DJD; K01TW011187).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The PrEP-PP study was approved by the Human Research Ethics Committee at the University of Cape Town (#297/2018) and by the University of California, Los Angeles Institutional Review Board (IRB#18-001622).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • § Contact information: Dvora Leah Joseph Davey, Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, 615 E Charles Young Drive S, Los Angeles, CA 90095. dvoradavey{at}ucla.edu, +1 (310) 701-1526

Data Availability

Data is available upon request from study investigators. Please email dvoradavey{at}ucla.edu for more information

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 04, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa
Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Jessica More, Linda-Gail Bekker, Pamina Gorbach, Thomas J. Coates, Landon Myer
medRxiv 2021.05.04.21256514; doi: https://doi.org/10.1101/2021.05.04.21256514
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa
Dvora Leah Joseph Davey, Rufaro Mvududu, Nyiko Mashele, Maia Lesosky, Nehaa Khadka, Jessica More, Linda-Gail Bekker, Pamina Gorbach, Thomas J. Coates, Landon Myer
medRxiv 2021.05.04.21256514; doi: https://doi.org/10.1101/2021.05.04.21256514

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (858)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8561)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1242)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10299)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1677)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (113)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (252)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1768)
  • Public and Global Health (3837)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (167)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)